Study wrapper · #742
Circulating Mitochondrial Open Reading Frame of the 12S Ribosomal RNA Type-c Is Higher in Acute Coronary Syndrome and Is a Prognostic Biomarker for Major Cardiac Events in Patients With Acute Myocardial Infarction: A Case-Control Study.
Editor's note
In a 400-subject case-control study, researchers found circulating MOTS-c was higher in acute coronary syndrome and, combined with an oxidative-stress marker, predicted major adverse cardiac events over 18 months. In-vitro work suggested oxidative stress induces MOTS-c while MOTS-c in turn reduces hypoxia-induced oxidative stress. The larger sample and prospective outcome tracking are strengths. But direction is complicated: here MOTS-c is elevated in disease, whereas other cardiac studies report it reduced, reinforcing that MOTS-c's biomarker behaviour is context-dependent and possibly compensatory. Associations cannot establish causation. Weight it as one of the sturdier human MOTS-c biomarker datasets while recognising it deepens, rather than resolves, the mixed cardiac picture.
Plain-language abstract
Researchers studied MOTS-c, a mitochondria-derived peptide, in 400 people split into three groups: healthy controls, those with unstable angina, and those with acute myocardial infarction (heart attack). They measured blood MOTS-c and an oxidative-stress marker, then followed patients for 18 months. MOTS-c was higher in people with acute coronary syndrome, and higher levels tracked with more oxidative stress. MOTS-c showed reasonable ability to flag who had heart trouble, and combined with the oxidative-stress marker it helped predict serious later heart events. Lab experiments suggested oxidative stress pushes MOTS-c up, while MOTS-c itself reduces stress from low oxygen, hinting it may be a compensating response. Notably, this study found MOTS-c raised in heart disease, whereas some other studies found it lowered, so the picture is genuinely mixed. Being an observational study, it cannot prove cause and effect. It is one of the larger human datasets on MOTS-c in heart disease.